Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines.

Serkan Atıcı Ahmet Soysal Erdem Gönüllü Gökhan Aydemir Cevat N Öner Servet Alan Havva Engin Melek Yıldız Metin Karaböcüoğlu

Published in: Revista da Sociedade Brasileira de Medicina Tropical (2023)

After the second dose of CoronaVac, protective neutralizing antibody levels decrease over time, and a booster dose is required. Heterologous COVID-19 booster vaccination with BNT162b2 is effective at boosting neutralizing antibody levels.

Keyphrases

immune response
coronavirus disease
sars cov
dengue virus
dna damage
saccharomyces cerevisiae
dendritic cells
respiratory syndrome coronavirus
dna repair
toll like receptor
oxidative stress
binding protein
clinical evaluation